Add it up yourself from the PR below ... 350mil/8bil = rough estimate of hit to future sales... i.e., a 5% drop would be more appropriate here... not 30%
HAYWARD, Calif.--(BW HealthWire)--Feb. 12, 2002--IMPAX Laboratories, Inc. IPXL today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Allegra-D(R) (Fexofenadine HCl/Pseudoephedrine HCl) Extended Release 60 mg/120mg Tablets.
Aventis Pharmaceuticals Inc. markets Allegra-D(R) for the relief of symptoms associated with seasonal rhinitis in adults and children 12 years of age and older. U.S. sales of Allegra-D(R) Extended Release Tablets were over $350 million in 2001. ...
IMPAX currently has fifteen ANDA filings pending at the FDA that address more than $8 billion in U.S. branded product sales. Nine of these filings were made under Paragraph IV of the Hatch-Waxman Amendments.